J. B. Chemicals & Pharmaceuticals Ltd up by 10.31 percent | Espresso

EspressoLogy

Espresso shot of the day – J. B. Chemicals and Pharmaceuticals Ltd up by 10.31 percent

July 02, 2021
Espresso shot of the day – J. B. Chemicals and Pharmaceuticals Ltd up by 10.31 percent

J. B. CHEMICALS AND PHARMACEUTICALS LTD 1864.35 (+10.31%) BSE – INE572A01028 | 2ND JULY 2021

Established in 1976, J B Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and international markets, JBCPL is trusted by healthcare professionals globally. Today, JBCPL exports to over 30 countries across the world and earns more than half its revenue from its international business. JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectables (vials, ampoules, form fill seal), creams and ointments, lozenges, herbal liquids and capsules. JBCPL has its headquarters in India’s financial capital, Mumbai. With a domestic sales force of 1,000, 17 internationally approved state of the art manufacturing units, a Research and Development Centre and subsidiaries abroad, the organisation is continually enhancing value for its shareholders. In Indian and international markets, JBCPL is also known as Unique Pharmaceutical Laboratories, which is a division of JBCPL.

Recent Drivers

  • On June 26, 2021, J B Chemicals & Pharmaceuticals Ltd. announced the launch of Nintabid capsules, an oral anti-fibrotic agent that slows the decline in forced vital capacity associated with Idiopathic Pulmonary Fibrosis (IPF).
  • On June 14, 2021, the Board of Directors of the Company at its meeting, has recommended a final dividend of Rs 8 (400%) per equity share of FV of Rs 2 for the year 2020-21. The dividend, if declared, will be remitted / dividend warrants will be dispatched on Sept 17, 2021.
  • JBCPL reported quarterly net profit at Rs 100.61 crores in March 2021, up 100.67% from Rs 50.14 crores in March 2020.
  • JBCPL reported net sales at Rs 528.46 crores in March 2021, up 19.14% from Rs 443.57 crores in March 2020.
  • On May 31, 2021, JBCPL announced the launch of NOSMOK prescription medicated nicotine lozenges as part of a 360° tobacco cessation initiative on World No Tobacco Day.
(Sources: Business Standard, Moneycontrol, BSEIndia, Medical Dialogues)


Technical Force*

  • S&P BSE500 month till date gain up by 0.15%
  • Traded on all-time-high value of 1897.15
  • 3 months avg. volume of NSE: 1,70,149
  • Quantity traded: 79,893 | Deliverable quantity: 17,576 (22%)
  • Stock price has jumped more than 160% from one-year-low level: 701.45 (July 3, 2020)
  • Daily RSI (14) is in Overbought territory today
  • 52-week-high: 1897.15 | 52-week-low: 701.45

Key Pivot  (Yearly)

R4

R3

R2

R1

PP /FIB PP

S1

S2

S3

S4

Pivot Point

-

2028.70

1589.35

1303.25

863.90

577.80

138.45

-

-

Fibonacci Pivot

1589.35

1312.23

1141.02

1030.75

863.90

697.05

586.78

415.57

138.45


Today’s Close

1864.35

SMA

BSE

10 DAY

1622.21

20 DAY

1577.87

50 DAY

1479.93

200 DAY

1170.17


Some Key Ratios (Source: BSE)

Market Cap: 14,408.09 crores

PE: 32.23

OPM%: 30.84

ROE%: 24.75

Promoters holding%: 55.91

Prev. Close: 1690.15

*Chart And Technical Force data taken from the Binge desktop app.

The scope and usability of this information/data is time-sensitive and market-based, and as such the same may become outdated for the investment decisions of clients, for which Sharekhan comtrade bears no responsibility. References to securities do not constitute a recommendation to buy, sell or hold such securities. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult his own advisors to determine the merits and risks of such an investment. Sharekhan Comtrade Private Limited is under no obligation to update the information in this document from time-to-time.



Chandresh Khona
by Chandresh Khona

Product Offerings Head

A teacher, writer, travel buff and now Espresso's Product Offerings Head. Ten years here has allowed me to lead the digital team at Sharekhan. My true passion lies in stock market charts.